98%
921
2 minutes
20
To evaluate the criteria used by allergists in selecting an immunotherapy extract (allergen immunotherapy [AIT]-extract) in rhinitis patients with polysensitization. First, a cross-sectional study was carried out by evaluating different factors that influence the medical choice of AIT-extract. Second, a literature review was performed by evaluating the diagnostic performance of atopy tests. A total of 419 patients were included (84 children, 149 adolescents and 186 adults). Anamnesis, atopy tests and exposure to pets were the main factors for choosing the AIT extract. The sensitivity and specificity of atopy tests were high for , (>80%), moderate for pets (60%) and indeterminate for . NCTs could be necessary for AIT-extract selection in polysensitized allergic rhinitis patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290366 | PMC |
http://dx.doi.org/10.1080/1750743X.2024.2342225 | DOI Listing |
Curr Opin Allergy Clin Immunol
August 2025
Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Purpose Of Review: The potential of allergen immunotherapy (AIT) to prevent allergic airway disease progression are demonstrated. Though not all patients benefit equally, there is limited research on which patients may benefit most.In this article, we focus on factors that may influence the risk of progression and their influence on the preventive effects of AIT, and whether some patients may benefit more than others may.
View Article and Find Full Text PDFJ Educ Health Promot
July 2025
Otolaryngology Department, The First People's Hospital of Yinchuan, Otolaryngology Head and Neck Surgery Hospital, Yinchuan, Ningxia, China.
Background: There are a few effective tools in China to assess the geography, diet, and symptoms of allergic rhinitis (AR) patients. Existing generic tools need cultural adaptation better to evaluate AR's impact on quality of life. This study aimed to develop the Quality-of-Life Questionnaire for AR patients (QoLAR), adapt it to Chinese, and assess its reliability and validity.
View Article and Find Full Text PDFRespir Med
September 2025
Department of Public Health and Infectious Diseases, Pulmonology Unit, Policlinico Umberto I, "Sapienza" University of Rome, 00185 Rome, Italy.
Purpose: Asthma and obstructive sleep apnea (OSA) are two respiratory diseases that often may coexist, resulting in Alternative Overlap Syndrome (aOVS), which is still underestimated and underdiagnosed.
Objectives: This state-of-art review aims to describe the current evidence on aOVS, including its pathophysiology, clinical, functional and therapeutic implications. A secondary objective is to assess whether aOVS can be identified as a distinct endophenotype needing personalized diagnostic and therapeutic strategies.
Am J Otolaryngol
May 2025
Department of Otorhinolaryngology Head and Neck Surgery, Hainan Affiliated Hospital of Hainan Medical University, Hainan General Hospital, Haikou, Hainan, China. Electronic address:
Background: Sublingual immunotherapy (SLIT) has been widely established as a disease-modifying treatment for allergic airway diseases. However, its efficacy and safety in allergic pharyngitis (AP) remain insufficiently investigated and require further clinical validation.
Methods: In this retrospective study, 100 patients diagnosed with house dust mite (HDM)-induced AP concomitant with allergic rhinitis (AR) were enrolled.
Int Forum Allergy Rhinol
September 2025
Division of Otolaryngology Head & Neck Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Background: Emerging evidence suggests a possible link between rhinosinusitis and systemic rheumatic diseases; however, no meta-analysis has comprehensively examined this association to date. We aimed to investigate if patients with rhinosinusitis have a predisposition to unmasking rheumatic diseases compared to individuals without rhinosinusitis.
Methods: A comprehensive search in MEDLINE, Embase, Cochrane Library, and Web of Science was conducted until February 2025 for studies characterizing rheumatic disease incidence, prevalence, and risk in cohorts of rhinosinusitis patients.